MorphoSys AG

Industry / private company


Location: Martinsried, Germany (DE) DE

ISNI: 0000000405539494

ROR: https://ror.org/00ew7rg06

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. (2024) Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, et al. Journal article Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial (2020) Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, et al. Journal article IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema (2020) Lauffer F, Jargosch M, Baghin , Krause L, Kempf W, Absmaier-Kijak M, Morelli M, et al. Journal article Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide (2019) Mougiakakos D, Völkl S, Bach C, Stoll A, Bitterer K, Beier F, Endell J, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway (2018) Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, et al. Journal article MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial (2015) Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, et al. Journal article